Vancouver, British Columbia--(Newsfile Corp. - February 11, 2021) - Algernon Pharmaceuticals Inc. (CSE: AGN) (OTCQB: AGNPF) - The company has concluded a trial for Ifenprodil and is expecting to report on the data by the end of February. They are hopeful that Ifenprodil will be found to reduce the severity and the duration of a COVID-19 infection.
If you cannot view the video above, please visit:
https://b-tv.com/algernon-pharmaceuticals-trial-complete-for-covid-19-treatment-news-alert-30sec/
Algernon Pharmaceuticals Inc. (CSE: AGN) (OTCQB: AGNPF)
Algernon Pharmaceuticals is being featured on BNN Bloomberg on Feb 15th to 28th, 2021, throughout the day and evenings.
algernonpharmaceuticals.com
About BTV:
BTV-Business Television is Canada's longest running business show. With Hosts Taylor Thoen and Jessica Katrichak, BTV features emerging companies across the country to bring viewers investment opportunities. BTV also produces News Alerts and branding/awareness spots for issuers broadcast on BNN Bloomberg, Fox Business News, Bloomberg TV US and Bloomberg Terminals. www.b-tv.com
BTV - Business Television/CEO Clips Contact: Trina Schlingmann (604) 664-7401 x 5 trina@b-tv.com
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/74282
